Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Indenolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indenolol SCHEMBL79023 | 0.98 | ADRB2 (0.56) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| Indenolol SCHEMBL79021 | 0.98 | ADRB2 (0.56) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| Indenolol SCHEMBL349116 | 0.96 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| Indenolol SCHEMBL349114 | 0.96 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| SCHEMBL11631654 | 0.90 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| SCHEMBL11656702 | 0.87 | ADRB2 (0.44) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| Idropranolol SCHEMBL1255318 | 0.86 | ADRB1 (0.54) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| Indenolol SCHEMBL11666579 | 0.84 | ADRB2 (0.48) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| SCHEMBL11754160 | 0.83 | ALOX15 (0.41) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL11659927 | 0.82 | ADRB2 (0.46) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1303306-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB1, ADRB2, ADRB3 | SLC6A2 637/4885SLC6A3 2232/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.